Armata Pharmaceuticals (ARMP) Stock Statistics & Valuation Metrics

Armata Pharmaceuticals has a market cap or net worth of $437.76M. The enterprise value is $717.09M.

Armata Pharmaceuticals has 36,632,774 shares outstanding. The number of shares has decreased by -2.65% in one year.

Armata Pharmaceuticals’s return on equity (ROE) is 0.80 and return on invested capital (ROIC) is -43.07%.

The current PE Ratio of Armata Pharmaceuticals is ―. Armata Pharmaceuticals’s PEG ratio is -0.00160.

In the last 12 months, Armata Pharmaceuticals had revenue of 4.90M and earned -173.80M in profits. Earnings per share was -4.80.

In the last 12 months, operating cash flow was -25.76M and capital expenditures -542.00K, giving a free cash flow of -26.30M billion.

Armata Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Armata Pharmaceuticals upcoming earnings date is May 7, 2026, TBA (Confirmed).

Armata Pharmaceuticals as a current ratio of 1.19, with Debt / Equity ratio of -131.76%

In the past 12 months, Armata Pharmaceuticals has paid 0.00 in taxes.

Armata Pharmaceuticals EV to EBITDA ratio is -17.07, with an EV/FCF ratio of -19.27.

Armata Pharmaceuticals has $8.69M in cash and marketable securities with $288.02M in debt, giving a net cash position of -$279.33M billion.

Gross margin is 68.78%, with operating margin of -636.66%, and net profit margin of -3544.03%.

The average price target for Armata Pharmaceuticals is $17.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy